Adenosine receptor antagonists - Pipeline Insight, 2024

This “Adenosine receptor antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Adenosine receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Adenosine receptor antagonists: Understanding

Adenosine receptor antagonists: Overview

Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders and cancer. After more than three decades of medicinal chemistry research, a considerable number of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clinically evaluated, although none has yet received regulatory approval. There are four known subtypes of adenosine receptors (ARs) - referred to as A1, A2A, A2B and A3 - each of which has a unique pharmacological profile, tissue distribution and effector coupling. All four subtypes are members of the superfamily of G-protein-coupled receptors (GPCRs), and are most closely related to the receptors for biogenic amines. Among the human ARs, the most similar are the A1 and A3 ARs (49% sequence similarity) and the A2A and A2B ARs (59% similarity). Selective antagonists have entered clinical trials for the treatment of Parkinson’s disease and congestive heart failure. Both in the case of diseases such as stroke, where there is an unmet medical need, and for diseases that already have pharmacological intervention options, the introduction of adenosine-based drug therapy will provide novel mechanisms for therapy.

“Adenosine receptor antagonists - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Adenosine receptor antagonists pipeline landscape is provided which includes the disease overview and Adenosine receptor antagonists treatment guidelines. The assessment part of the report embraces, in depth Adenosine receptor antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adenosine receptor antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Adenosine receptor antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Adenosine receptor antagonists.

Adenosine receptor antagonists Emerging Drugs Chapters

This segment of the Adenosine receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Adenosine receptor antagonists Emerging Drugs

Inupadenant: i Teos Therapeutics Elevated levels of adenosine found in the tumor microenvironment are known to be immunosuppressive, by inhibiting A2AR, the only high-affinity adenosine receptor expressed on different immune cells found in the tumor micro-environment. Inupadenant (EOS-850) is the first insurmountable A2AR antagonist tailored for application in immuno-oncology, currently in clinical development. Inupadenant was designed by iTeos’ scientists to remain potent at the high adenosine concentrations found in the tumor micro-environment and maintain continuous target coverage in multiple tumor types. Inupadenant has a very high selectivity for A2AR compared to the other adenosine receptors and is non brain penetrant, two characteristics that should improve its safety. With this profile, we believe that inupadenant has the potential for enhanced antitumor activity as compared to other A2AR antagonists currently in clinicaldevelopment.

Etrumadenant: Arcus Biosciences Etrumadenant is a small molecule, selective dual antagonist of the A2a and A2b receptors that can prevent adenosine-mediated immunosuppression. Once the immunosuppressive effects of adenosine are blocked, activation of anti-tumor immune cells may be restored resulting in tumor cell death. Etrumadenant is a dual adenosine A2a/A2b receptor antagonist in Phase I and Phase II studies in NSCLC, colon cancer and prostatecancer.

Adenosine receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Adenosine receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Adenosine receptor antagonists

There are approx. 12+ key companies which are developing the therapies for Adenosine receptor antagonists. The companies which have their Adenosine receptor antagonists drug candidates in the most advanced stage, i.e. Phase II include, i TeosTherapeutics.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Adenosine receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Adenosine receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adenosine receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adenosine receptor antagonists drugs.

Adenosine receptor antagonists Report Insights

• Adenosine receptor antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Adenosine receptor antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Adenosine receptor antagonists drugs?
• How many Adenosine receptor antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adenosine receptor antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Adenosine receptor antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Adenosine receptor antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Arcus Biosciences
• KLUS Pharma Inc.
• i TeosTherapeutics
• Calixar
• AstraZeneca
• Domain Therapeutics
• ENDACEA
• Teon Therapeutics
• Portage Biotech Inc.
• Corvus Pharmaceuticals

Key Products

• Etrumadenant
• A295
• Inupadenant
• AZD4635
• M1069
• Research Program
• L-97-1
• TT-702
• PORT-6
• PORT-7
• PORT-8
• V81444

This product will be delivered within 1-3 business days.